文献速递免疫规划

PastoCoAd候选疫苗的效力、毒性与保护性评价:新型临床前混合匹配rAd5 S、rAd5 RBD-N与SOBERANA二聚体RBD蛋白

Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
PubMed 文献 · Vaccine · 2022-04-04

本研究开发了三种基于腺病毒载体和SOBERANA二聚体RBD蛋白的PastoCoAd候选疫苗(prime-boost、异源prime-boost和prime-only),在小鼠、兔和仓鼠模型中评价免疫原性,在仓鼠模型中评价保护性。结果显示候选疫苗无显著组织毒性,prime-only和异源prime-boost疫苗的总IgG抗体反应显著高于其他组(P < 0.009),攻毒后接种仓鼠咽部和肺组织病毒滴度显著降低。

要点

  • 候选疫苗在小鼠、兔和仓鼠中诱导总IgG抗体、病毒中和抗体及细胞免疫反应。
  • prime-only和异源prime-boost疫苗的总IgG抗体反应显著高于其他组(P < 0.009)。
  • 攻毒试验中接种仓鼠咽部和肺组织病毒滴度较对照组显著降低。

核心结论

  • 异源prime-boost疫苗(腺病毒载体/SOBERANA RBD)以及单剂腺病毒载体疫苗在动物模型中显示出安全性和保护性。

研究设计与样本

  • 开发了三种SARS-CoV-2候选疫苗:prime-boost(rAd5-S/rAd5 RBD-N)、异源prime-boost(rAd5-S/SOBERANA疫苗)和prime-only(rAd5-S与rAd5 RBD-N混合物)。
  • rAd5-S和rAd5 RBD-N使用巨细胞病毒启动子和人组织型纤溶酶原激活剂(tPA)前导序列生产。
  • 在小鼠、兔和仓鼠模型中评价免疫原性,在仓鼠模型中评价保护性。

主要发现

  • 注射候选疫苗后,动物模型组织中未观察到显著毒性。
  • 小鼠、兔和仓鼠的免疫原性研究显示,prime-only和异源prime-boost疫苗的总IgG抗体反应显著高于其他组(P < 0.009)。
  • 所有接种模型均检测到病毒中和抗体,与体液免疫和细胞免疫相关的细胞因子水平显著升高。
  • 与对照组相比,接种组显示出高的细胞免疫反应。
  • 疫苗攻毒试验显示,与对照组相比,接种仓鼠的咽部和肺组织病毒滴度显著降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite substantial efforts, no effective treatment has been discovered for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. Therefore, vaccination to reach herd immunity is the ultimate solution to control the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to evaluate the potency, toxicity, and protection of candidate PastoCoAd vaccines as novel mix and match of recombinant adenovirus type 5 (rAd5) containing the full-length spike protein (rAd5-S), rAd5 containing the receptor-binding domain of S protein and nucleoprotein (rAd5 RBD-N), and SOBERANA dimeric RBD protein of SARS-CoV-2. Three vaccine candidates were developed against SARS-CoV-2 using adenoviral vectors, including the prime-boost (rAd5-S/rAd5 RBD-N), heterologous prime-boost (rAd5-S/ SOBERANA vaccine), and prime only (mixture of rAd5-S and rAd5 RBD-N). The rAd5-S and rAd5 RBD-N were produced with a Cytomegalovirus promoter and the human tissue plasminogen activator (tPA) leader sequence. The immunogenicity of vaccine candidates was also evaluated in mouse, rabbit, and hamster models and protection was evaluated in a hamster model. Following the injection of vaccine candidates, no significant toxicity was observed in the tissues of animal models. The immunogenicity studies of mice, rabbits, and hamsters showed that responses of total IgG antibodies were significantly higher with the prime-only and heterologous prime-boost vaccines as compared to the other groups (P < 0.009). Virus neutralizing antibodies were detected, and the level of cytokines related to humoral and cellular immunity increased significantly in all vaccinated models. A high cellular immunity response was found in the vaccinated groups compared to the controls. On the other hand, the vaccine challenge test showed that the virus titers significantly decreased in the pharynx and lung tissues of vaccinated hamsters compared to the control group. These successful findings suggest the safety and protection produced by the heterologous prime-boost vaccine (adenovector/ SOBERANA RBD), as well as a single dose of adenovector vaccine in animal models.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hassan PM, Ali T, Saber E, et al. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein. Vaccine. 2022. PMID: 35393148. doi:10.1016/j.vaccine.2022.03.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。